Shopping Cart

Your shopping cart is currently empty

Amrinone

Name: Amrinone
Brand: TargetMol
SKU: T1265
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Catalog No. T1265Cas No. 60719-84-8

Alias Wincoram, Inocor, Inamrinone

Amrinone (Inocor) is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity.

Amrinone

Copy Product Info

🥰Excellent

Purity: 99.45%

Catalog No. T1265Alias Wincoram, Inocor, InamrinoneCas No. 60719-84-8

Amrinone (Inocor) is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity.

Pack Size	Price	USA Warehouse	Global Warehouse
50 mg	$39	In Stock	In Stock
100 mg	$56	In Stock	In Stock
500 mg	$133	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$30	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.45%

Color:White

Resource Download

COA

Product Introduction

Amrinone AI Summary

Amrinone exhibits positive inotropic activity in both anesthetized dogs (ED50 = 0.389 mg/kg) and isolated papillary muscle of dogs, indicating an increase in myocardial contractility. It inhibits various forms of phosphodiesterase (PDE) with notable inhibitory concentrations (IC50 values) including: - PDE3 from guinea pig heart: IC50 = 50000.0 nM - PDE3 in dog aorta: IC50 = 28000.0 nM - PDE4 from the heart: IC50 = 101000.0 nM - PDE1 from the cerebral cortex: IC50 > 300000.0 nM The compound also significantly affects contractile force and frequency rate in spontaneous beating atria from Reserpine-treated guinea pigs, demonstrating an increase in both parameters at different concentrations. It has bioactivities related to hemodynamic activity, showing a dose-dependent increase in left ventricular myocardial activity in anesthetized dogs, and exhibits a significant inhibitory effect on ADP-induced platelet aggregation at higher concentrations. Additionally, Amrinone has moderate lipophilicity with a LogP value of 2.66 and shows good oral bioavailability in humans (>80%). The compound's pharmacokinetic profile indicates a high clearance rate (8.9 mL.min^-1.kg^-1) and a short half-life (T1/2 = 2.0 hr), suggesting a relatively short duration of action. On the cardiovascular side, it also demonstrates selectivity and potency against cAMP PDE III enzyme over PDE I and II, and shows significant liver metabolism markers, with effects observed on enzymes such as SGOT and SGPT. Furthermore, the compound's inhibition of human BSEP activity and its interaction with various transporters like P-gp and MRP2 hints at its complex absorption and distribution characteristics. In antiviral contexts, it shows marginal activity against SARS-CoV-2 induced cytotoxicity in Caco-2 cells, suggesting a limited antiviral potential. Overall, Amrinone demonstrates promising cardiotonic properties and PDE inhibition but requires further evaluation for its multi-target bioactivities, including its antiviral potential and liver toxicity profile..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Amrinone (Inocor) is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity.
Synonyms	Wincoram, Inocor, Inamrinone

Chemical Properties

Molecular Weight	187.2
Formula	C₁₀H₉N₃O
Cas No.	60719-84-8
Smiles	NC1=CC(=CNC1=O)C=2C=CN=CC2
Relative Density.	1.277 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 25 mg/mL (133.55 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (5.34 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	5.3419 mL	26.7094 mL	53.4188 mL	267.0940 mL
5 mM	1.0684 mL	5.3419 mL	10.6838 mL	53.4188 mL
10 mM	0.5342 mL	2.6709 mL	5.3419 mL	26.7094 mL
20 mM	0.2671 mL	1.3355 mL	2.6709 mL	13.3547 mL
50 mM	0.1068 mL	0.5342 mL	1.0684 mL	5.3419 mL
100 mM	0.0534 mL	0.2671 mL	0.5342 mL	2.6709 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc